Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI in Biliary Tract Cancer
NCT01494363Phase 2Unknown
- Sponsor
- Soonchunhyang University
- Start
- Oct 2011
- Primary completion
- Dec 2013
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in biliary tract cancer (BTC), sponsored by Soonchunhyang University. Status: unknown.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT01494363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01494363.